CytomX Therapeutics to Announce Third Quarter 2021 Financial Results on November 4, 2021
CytomX Therapeutics, Inc. (Nasdaq: CTMX) announced their upcoming third quarter 2021 financial results on November 4, 2021, following U.S. market closure. A conference call at 5:00 p.m. ET will provide insights into the results and corporate updates. CytomX is focused on developing conditionally activated therapeutics via their Probody® technology platform, aiming to improve cancer therapy effectiveness while minimizing toxicity. The company collaborates with industry leaders like AbbVie and Bristol Myers Squibb, having a pipeline with multiple assets in Phase 2 clinical trials.
- Collaboration with major pharmaceutical companies like AbbVie and Bristol Myers Squibb.
- Multiple assets in Phase 2 clinical studies aimed at innovative cancer treatments.
- Probody® technology platform designed to enhance safety and efficacy of cancer therapies.
- None.
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today announced that it will report third quarter 2021 financial results on Thursday, November 4, 2021, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and provide a corporate update.
Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations. An archived replay of the webcast will be available on the Company’s website until November 11, 2021.
Audio Conference Call:
| U.S. Dial-in Number: | (877) 809-6037 | |
| International Dial-in Number: | (615) 247-0221 | |
| Conference ID: | 3886792 |
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. We are developing a novel class of investigational conditionally activated therapeutics, based on our Probody® technology platform, for the treatment of cancer. CytomX has strategic drug discovery and development collaborations with AbbVie, Amgen, Astellas, and Bristol Myers Squibb.
Probody therapeutics are conditionally activated biologics designed to remain inactive until they are activated by proteases in the tumor microenvironment. As a result, Probody therapeutics are intended to bind selectively to tumors and decrease binding to healthy tissue, to minimize toxicity and potentially create safer, more effective therapies. As leaders in the field, our innovative technology is designed to turn previously undruggable targets into druggable targets and to enable more effective combination therapies. CytomX and its partners, comprised of leading biotechnology and pharmaceutical companies, have developed a robust pipeline of potential first-in-class therapeutic candidates against novel, difficult to drug targets and potential best-in-class immunotherapeutic candidates against clinically validated targets. The CytomX clinical-stage pipeline comprises five assets, four of which are in Phase 2 clinical studies. First-in-class product candidates against previously undruggable targets include a CD166-targeting conditionally activated antibody-drug conjugate wholly owned by CytomX (praluzatamab ravtansine, CX-2009) and a CD71-targeting conditionally activated antibody-drug conjugate partnered with AbbVie (CX-2029). CD166 and CD71 are among cancer targets that are considered to be inaccessible to conventional antibody-drug conjugates due to their presence on many healthy tissues. The CytomX clinical-stage pipeline also includes cancer immunotherapeutic candidates against validated targets such as the CTLA-4-targeting Probody therapeutics, BMS-986249 and BMS-986288, partnered with Bristol Myers Squibb, and our wholly-owned conditionally activated anti-PD-L1 antibody, pacmilimab (CX-072). For additional information about CytomX Therapeutics, visit www.cytomx.com and follow us on LinkedIn and Twitter.
Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.
Investor Contact:
Chau Cheng, PhD MBA
VP, Investor Relations & Corp. Communications
ccheng@cytomx.com
Direct: (650) 273-4999
Media Contact:
Bret Coons
Director, Corporate Communications
bcoons@cytomx.com
Direct: (650) 528 2929
FAQ
When will CytomX Therapeutics report their Q3 2021 financial results?
What time is the conference call for CytomX's financial results?
What is the stock symbol for CytomX Therapeutics?
Where can I access the live webcast of CytomX's conference call?
What is the focus of CytomX Therapeutics?
